TriSalus Life Sciences, Inc. (TLSI) Gross Margin
- Gross margin · 12 months: Value 85.79%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 85.79% | Gross profit / revenue. Period ending 2026-06-30. $38.67M ÷ $45.08M × 100 ≈ 85.79% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 38.67M USD | Gross Profit |
| Revenue | 45.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.41M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $38.67M | $45.08M | $6.41M | 85.79% |
| 2026-03-31 | $38.18M | $44.88M | $6.70M | 85.07% |
| 2025-12-31 | $38.19M | $45.15M | $6.96M | 84.57% |
| 2025-09-30 | $33.79M | $40.21M | $6.42M | 84.04% |
| 2025-06-30 | $30.47M | $35.99M | $5.52M | 84.67% |
| 2025-03-31 | $27.51M | $32.14M | $4.63M | 85.60% |
| 2024-12-31 | $25.33M | $29.43M | $4.10M | 86.06% |
| 2024-09-30 | $23.42M | $26.89M | $3.47M | 87.10% |
| 2024-06-30 | $21.68M | $24.74M | $3.05M | 87.65% |
| 2024-03-31 | $19.07M | $21.98M | $2.91M | 86.74% |
| 2023-12-31 | $15.91M | $18.51M | $2.60M | 85.93% |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | $10.14M | $12.40M | $2.26M | 81.79% |
| 2022-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |